Search Filters

  • Presentation Format
  • Media Type
  • Diagnosis / Condition
  • Diagnosis Method
  • Patient Populations
  • Treatment / Technique

Midterm Patient-Reported Outcomes Of A Single-Surgery Treatment Of Knee Cartilage Lesions With Primary Autologous Articular Chondrocytes Co-Implanted With Bone-Marrow Cells In A Hyaluronan Scaffold


Emmanouil Papakostas, MD, FEBSM
QATAR

Midterm Patient-Reported Outcomes Of A Single-Surgery Treatment Of Knee Cartilage Lesions With Primary Autologous Articular Chondrocytes Co-Implanted With Bone-Marrow Cells In A Hyaluronan Scaffold

Emmanouil Papakostas, MD, FEBSM, QATAR Ioannis Terzidis, Prof., MD, PhD, BSc, FEBSM, GREECE Aristotelis Sideridis, MD, GREECE Efthymios Papasoulis, MD, GREECE Argyris Karavelis, MD, GREECE Willem Cornelis de Jong, PhD, NETHERLANDS Roderick Polak, UNITED KINGDOM

TheMIS Orthopaedic Center, Thessaloniki, GREECE

2021 Congress   ePoster Presentation     Not yet rated

 

Anatomic Location

Knee

Anatomic Structure

Cartilage

Diagnosis / Condition

Trauma

Treatment / Technique

Biologics Arthroscopy Implant Stem Cell Therapy

Diagnosis Method

Physical Examination MRI

Sports Medicine

Outcome Studies

Cartilage

Cartilage Treatment Cartilage Injuries

This media is available to current ISAKOS Members, Global Link All-Access Subscribers and Webinar/Course Registrants only.
Log inSubscription Options

Summary: Novel single-surgery autologous-chondrocyte-based treatment of knee cartilage lesions improves PROMs up to 5 years post surgery

Single-surgery treatment of knee-cartilage lesions with primary autologous articular chondrocytes (PCs) and mononuclear bone-marrow cells (MNCs) is promising, but midterm clinical results are scarce. We here report KOOS and IKDC outcomes, as well as patient satisfaction levels, of up to 5 years after surgery of a prospective case series of sixteen patients with single or multiple symptomatic knee-cartilage lesions of modified Outerbridge grades III or IV. Mean baseline age (± SD) was 37 (± 11) years; mean total lesion area (± SD) was 4.4 (± 2.7) cm2. PCs and MNCs were applied intraoperatively on a hyaluronan scaffold. One patient was treated for both knees (n = 17 knees). KOOS Pain, Sport&Rec, and QoL were improved significantly over baseline at 12 months and then again at 3 to 5 years post surgery. KOOS Symptoms and ADL, and the IKDC stayed significantly improved from 12 months to 5 years. All: sphericity-corrected RMANOVA, Bonferroni post-hoc, p < 0.05. Mean ± SD improvements at last follow-up (3-5 years): KOOS Pain 25.5 ± 20.9, Symptoms 27.8 ± 19.0, ADL 26.8 ± 19.2, Sport&Rec 40.0 ± 35.7, QoL 38.8 ± 31.0, and IKDC (in %) 98.9 ± 105.7. Patient satisfaction levels (available for 16 knees): very much, 7; much, 4; mildly, 4; not, 1. Our results indicate that the treatment is clinically effective and mostly satisfactory at midterm. Quantitative biochemical analysis of the repair tissue achieved with single-stage intralesional application of primary autologous articular chondrocytes will be relevant to measure the treatment’s full potential.

More 2021 Congress Knee Abstract Presentations

More ISAKOS 2021: Global Content